By Adria Calatayud

Hikma Pharmaceuticals PLC said Thursday that talks have ceased over a potential acquisition of GlaxoSmithKline PLC's pharmaceutical and consumer businesses in Egypt and pharmaceutical business in Tunisia.

FTSE 100 pharmaceutical company Hikma said it won't be launching a mandatory tender offer process to acquire shares in GlaxoSmithKline SAE Egypt.

Hikma in January said that it had entered into a preliminary agreement with GSK's Egyptian subsidiary.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

March 11, 2021 09:02 ET (14:02 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Hikma Pharmaceuticals
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Hikma Pharmaceuticals